Roth Positive on Expansion of STAR Study Sites; Afforms Cytori (CYTX) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $6 after CYTX announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
